AVITA MEDICAL WKN: A0Q40S ISIN: AU000000AVH4 Kürzel: AVMXF Forum: Aktien Thema: Hauptdiskussion

https://clinicaltrials.gov/ct2/results?cond=&term=Recell&cntry=&state=&city=&dist=

Great statistics were presented at the meeting. A few listed here: Best of the Best Abstract – Pediatric Burn Care Dr. Carter presented data showing that 98% of mixed-depth/full-thickness burn Injuries in pediatric patients treated using Spray-On Skin Cells in combination with widely spaced meshed autografts were healed within four weeks of treatment. The presentation, titled “Evaluation of a Pediatric Population Treated for Burn Injuries Using an Autologous Skin Cell Suspension: Interim Analysis,” described the interim outcomes for 23 pediatric patients with a median age of 6.7 years old (ranging from 0.8 to 16.0) treated under FDA-IDE approved Compassionate Use and Continued Access programs. In patients with extensive burn injuries, lack of available donor skin is a major limitation achieving permanent closure; and the longer a wound remains open, the more susceptible a patient is to infection. In the U.S., one-third of burn injuries occur in children, and the availability of donor skin for traditional meshed autografts is even more limited in pediatric patients with extensive injuries. The use of the RECELL System, a donor skin sparing technology that enables rapid definitive closure of burn wounds, has the potential to improve patient outcomes. In this study of pediatric patients which included those with life-threatening thermal burn injuries, Spray-On Skin Cells prepared using the RECELL System were applied in combination with widely meshed split-thickness autografts to achieve definitive closure using minimal donor skin. A total of 107 burn injuries were treated in the study, and 98% achieved definitive healing within four weeks of treatment. Importantly, for patients with greater than 50% total body surface area (TBSA) burns, treatment with the combination of Spray-On Skin Cells and widely meshed split-thickness autografts achieved the same high rate of healing at week four as patients with smaller burns (burns equal to or less than 50% TBSA) treated with the same combination. In addition, in the study the donor sites on all patients were treated with Spray-On Skin Cells, and 62.5% of the donor sites were healed within a week of treatment, and 100% were completely healed within two weeks of treatment. “This interim analysis supports the use of the RECELL System as a viable option for treatment in these deeper burn injuries in pediatric patients,” said Dr. Carter. “In this vulnerable patient population, we observed excellent clinical outcomes with 98% of wounds healing within four weeks of treatment, and with the majority of burn sites having cosmetic outcomes rated as satisfactory or equivalent compared to uninjured skin. The early healing of donor sites contributed to a decrease between harvest times for patients with limited donor skin availability.” https://www.bioportfolio.com/news/article/3951694/AVITA-Medical-Announces-Presentation-at-ABA-Meeting-Highlighting-Results-of-Study-Using.html?utm_source=dlvr.it&utm_medium=***

https://www.abc15.com/news/valley-woman-continues-recovery-from-rare-flesh-eating-bacteria-infection

https://www.aknenarben.net/recell.html

f.o.o.l.

https://www.***.com.au/2019/04/10/why-the-avita-medical-share-price-crashed-29-lower-today/

https://www.news-medical.net/news/20190408/AVITA-Medical-presents-results-highlighting-outcomes-for-pediatric-burn-patients-treated-using-RECELL-System.aspx

https://recellsystem.com/

f.o.o.l.

https://www.***.com.au/2019/04/09/why-the-avita-medical-share-price-is-up-575-in-2019/

Einfach bei den Sternchen einsetzen, dann passt der Link. Danke odi001, wie immer top recherchiert!

Was heißt...f.o.o.l bitte

f.o.o.l.

https://www.***.com.au/2019/04/08/why-atomos-avita-medical-resolute-volpara-shares-surged-higher-today/

https://www.asx.com.au/asx/statistics/displayAnnouncement.do?display=pdf&idsId=02094093

https://www.asx.com.au/asx/statistics/displayAnnouncement.do?display=pdf&idsId=02094070